Cellectis SA
ALCLS
Company Profile
Business description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Contact
8, rue de la Croix Jarry
Paris75013
FRAT: +33 181691600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
229
Stocks News & Analysis
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
Why earnings growth might be more important when assessing frothy market conditions.
stocks
Are negative AI narratives holding this ASX share back?
This company is unlikely to be disrupted by AI
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,019.50 | 15.80 | -0.17% |
| CAC 40 | 8,367.33 | 17.54 | -0.21% |
| DAX 40 | 24,626.89 | 44.33 | -0.18% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,484.22 | 23.80 | -0.23% |
| HKSE | 22,741.82 | 284.86 | -1.24% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,116.82 | 648.71 | 0.93% |
| NZX 50 Index | 13,623.30 | 77.74 | 0.57% |
| S&P 500 | 7,440.43 | 86.41 | 1.18% |
| S&P/ASX 200 | 8,817.90 | 13.60 | -0.15% |
| SSE Composite Index | 4,064.19 | 9.72 | -0.24% |